REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sopheon Deployed Globally at The 3M Company

2 Jun 2021 07:00

RNS Number : 4875A
Sopheon PLC
02 June 2021
 

SOPHEON PLC

("Sopheon" or the "Company")

 

Sopheon Announces Global Deployment of Enterprise Innovation Management Solution at The 3M Company

 

3M manages its global portfolio of innovation and growth initiatives using Sopheon Accolade®

 

Sopheon has today announced that The 3M Company (NYSE: MMM) a long-standing customer of the group, is using its Accolade software for new product development throughout its global enterprise. 3M's cross-functional innovation teams rely on Sopheon Accolade to streamline processes, manage risk, optimize decision-making and accelerate time to market.

3M produces over 60,000 products under several brands and is a leader in consumer products, safety and industrial, healthcare, transportation, and electronics. 3M's deployment of Sopheon Accolade is enterprise-wide, including every division and business group across the company. This implementation involves thousands of users at all levels of the business, including research and development (R&D) scientists and researchers, manufacturing, supply chain, finance, sales and marketing, as well as commercialization managers and senior executives.

"R&D is the heartbeat of 3M," said Elizabeth Edblom, Ph.D., Director, Corporate Research & Development Global Strategy and New Growth at 3M. "Innovation is the thread that connects our four business groups to the vast amount of science conducted by the thousands of scientists and researchers we have around the world. The unprecedented enterprise-wide transparency provided by the Sopheon Accolade platform allows us to know what's going on in new product commercialization before, during and after launch. Additionally, Accolade's unique portfolio management capabilities provide business leaders with planning and performance insights required to govern the millions of dollars 3M invests in innovation. Finally, 3M is proud of our Sustainability Value Commitment for all new products - and Sopheon Accolade helps make that possible."

Accolade is Sopheon's award-winning innovation management platform that connects people, systems and information across departments and functions. This collaboration and synchronization results in trusted, timely data for faster, better and more dynamic decision making. In addition to 3M, Sopheon Accolade has proven its value to thousands of other global users, such as Honeywell, Merck KGaA, P&G, Philips, BASF, Parker Hannifin and other innovation and market leaders across a wide variety of industries.

"3M's commitment to innovation is extraordinary," said Greg Coticchia, CEO, Sopheon. "With 8,000 scientists and researchers working on 51 technology platforms in 650 different countries, it's essential that they have a global system that allows engagement and visibility among all functions. In addition to enabling the alignment of strategy and execution, the configurability of Accolade allowed 3M to deploy a system that ensures the organization remains focused on outcomes and not processes."

 

 

For further information contact:

Andy Michuda (Executive Chairman)Arif Karimjee (CFO)

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes/Edward Whiley (Corporate Finance)Alice Lane/Sunila da Silva (ECM)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

Sopheon and Accolade are trademarks of Sopheon plc. Stage-Gate® is a registered trademark of Stage-Gate Inc.

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.  

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFIRRLILIIL
Date   Source Headline
11th Apr 20167:00 amRNSDirectors Options and Shareholding
21st Mar 20167:00 amRNSAmendment to Terms of Convertible Loan Stock
17th Mar 20167:00 amRNSFinal Results
21st Jan 20168:29 amRNSAccolade Release 10.2
8th Jan 20167:00 amRNSTrading Update and Board Change
20th Oct 20159:33 amRNSDirector Dealing
19th Oct 20157:00 amRNSDirector Dealing
9th Oct 20153:41 pmRNSDirector Dealing
9th Oct 20151:12 pmRNSDirector Dealing
2nd Oct 20153:39 pmRNSDirector Dealing
23rd Sep 20157:00 amRNSAccolade Release 10.1
27th Aug 20157:01 amRNSHalf Yearly Report
1st Jul 20157:00 amRNSDirector Shareholding
10th Jun 20151:44 pmRNSResult of AGM
10th Jun 20157:00 amRNSAGM Statement
2nd Jun 20157:00 amRNSAccolade 10.0 release
15th May 20153:10 pmRNSNotice of AGM
7th May 201511:40 amRNSDIRECTOR SHAREHOLDING
23rd Apr 201511:10 amRNSDirector Shareholding
20th Apr 201511:43 amRNSDirector Shareholding
13th Apr 20152:03 pmRNSHolding(s) in Company
10th Apr 201511:05 amRNSHolding(s) in Company
8th Apr 20157:00 amRNSDELISTING FROM ALTERNEXT AMSTERDAM
19th Mar 20157:00 amRNSFinal Results
20th Feb 20157:00 amRNSSopheon Releases Accolade® 9.3
5th Feb 20154:12 pmRNSChange of Registered Office
28th Jan 20157:00 amRNSTrading Update
19th Dec 201410:30 amRNSResult of General Meeting
12th Dec 20143:00 pmRNSTrading Update
2nd Dec 20144:00 pmRNSProposed Share Subdivision
2nd Dec 20147:00 amRNSDirector/PDMR Shareholding
27th Oct 20144:15 pmRNSDirector/PDMR Shareholding
22nd Oct 20143:45 pmRNSDirector/PDMR Shareholding
21st Oct 20147:00 amRNSDirector/PDMR Shareholding
17th Oct 20141:50 pmRNSDirector/PDMR Shareholding
10th Oct 201411:15 amRNSResult of GM and Further re Share Consolidation
24th Sep 20147:00 amRNSAccolade 9.2 Release
12th Sep 20147:00 amRNSShare Consolidation
28th Aug 20147:00 amRNSHalf Yearly Report
11th Jun 201412:20 pmRNSResult of AGM
11th Jun 20147:00 amRNSAGM Statement
2nd Jun 20147:00 amRNSAmendment To The Terms Of Convertible Loan Stock
22nd May 20147:00 amRNSAlternext Amsterdam
1st May 20147:00 amRNSInterim Management Statement
22nd Apr 20147:01 amRNSSopheon Delivers Accolade Release 9.1
11th Apr 20147:00 amRNSWind Down Of Alternext Amsterdam
20th Mar 20147:01 amRNSTotal Voting Rights
20th Mar 20147:00 amRNSPreliminary Results
6th Mar 20147:00 amRNSNew Debt Facility
29th Jan 20148:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.